Nkarta (Nkarta) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nkarta FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nkarta's Free Cash Flow for the three months ended in Dec. 2023 was $-30.16 Mil. Nkarta's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Nkarta's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Nkarta's current FCF Yield % is -23.45%.

The historical rank and industry rank for Nkarta's FCF Margin % or its related term are showing as below:

During the past 6 years, the highest FCF Margin % of Nkarta was -90.72%. The lowest was -17647.83%. And the median was -8869.28%.

NKTX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.24
* Ranked among companies with meaningful FCF Margin % only.

Nkarta FCF Margin % Historical Data

The historical data trend for Nkarta's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta FCF Margin % Chart

Nkarta Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-17,647.83

Nkarta Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nkarta's FCF Margin %

For the Biotechnology subindustry, Nkarta's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nkarta's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nkarta's FCF Margin % falls into.

Nkarta FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nkarta's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-114.307	/	0
	=	%

Nkarta's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-30.161	/	0
	=	%

Nkarta FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nkarta's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nkarta (Nkarta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080

Website

https://www.nkartatx.com

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Executives

Paul J Hastings	director, officer: See Remarks	61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook	officer: Chief Medical Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager	officer: Chief Legal Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger	officer: Sr. VP, Technical Operations	6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager	officer: Chief Scientific Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin	officer: See Remarks	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood	officer: Chief Business Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam	officer: Chief Medical Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900